GENERAL MEETING OF SHAREHOLDERS OF TERAPLAST S.A.— Budget 2024

26 april 2024 **TeraPlast**



Key premises for 2024

- We will pursue cautious organic growth following the experience of recent years.
- For infrastructure works, fueled by public and European funds, a positive evolution is expected.
- The share of main expenses in turnover will be similar to that of 2023. The same goes for the share of business segments.
- We are reducing fixed costs for businesses that have experienced operational losses.
- The main contribution to the improvement in results will come from recent acquisitions Plaplast and the Freiler Group with +15% turnover and EBITDA, respectively.
- Volumes will increase by 16% for current businesses and by 33% together with the contribution of M&A.
- TeraBio Pack has reached the critical volume threshold and will enter positive profitability territory in 2024. The contribution of stretch films to the turnover of the segment will result in an 80% growth. However, from an EBITDA perspective, the ramp-up of the Opal stretch film factory will have a negative contribution.

TURNOVER 864,5 MLN. LEI

+29% compared to 2023 (672,3 mln. LEI)

EBITDA 71,7 MLN. LEI

+39%% compared to 2023 (51,4 mln. LEI)

EBITDA MARGIN

8,3%

+0,7pp compared to 2023 (7,6%)

NET PROFIT

10,6 MIL. LEI

+836% compared to 2023 (1,1 mln. LEI)

GROSS MARGIN

37%

2023 (37%)

QUANTITIES

100.127 TONS

+33% compared to 2023 (75.346 tons)







2024 Budget - segments

RON '000	2022	2023	2024 B
Net Sales	711.126	672.331	864.518
Other operating income	655	1.835	139
Total Operating Income	711.781	674.165	864.657
Raw materials, consumables & merchandise	(486.499)	(424.942)	(545.111)
Salaries and employee benefits	(83.556)	(95.056)	(116.432)
Utilities	(21.128)	(32.593)	(42.400)
Amortization, impairments, provisions	(26.285)	(33.002)	(36.491)
Other operating expenses	(67.880)	(70.203)	(89.057)
Total Operating Costs	(685.349)	(655.796)	(829.491)
EBIT	26.433	18.369	35.166
EBITDA	52.718	51.372	71.657
EBITDA %	7%	8%	8%
Financial result, net	(9.877)	(13.167)	(17.017)
Profit before tax	16.556	5.202	18.149
Income tax expense	(1.182)	(4.064)	(7.500)
Net Profit	15.374	1.138	10.649
Net Profit %	2%	0%	1%

For this year, TeraPlast Group presents a budget with moderated organic growth, based on the prior years experience and the current macroeconomic context. The expectations are that several market segments will face contractions on various levels, while public works, with governmental or European financing will be on the upswing.









2024 Budget - quarters

RON '000	2024 Budget	Q1	Q2	Q3	Q4
Net Sales	864.518	148.736	228.750	269.517	217.515
Other operating income	139	-	46	46	46
Total Operating Income	864.657	148.736	228.797	269.564	217.561
Raw materials, consumables & merchandise	(545.111)	(95.124)	(144.289)	(168.805)	(136.892)
Salaries and employee benefits	(116.432)	(24.291)	(29.398)	(30.260)	(32.483)
Utilities	(42.400)	(7.362)	(11.639)	(12.233)	(11.165)
Amortization, impairments, provisions	(36.491)	(8.158)	(9.431)	(9.486)	(9.416)
Other operating expenses	(89.057)	(19.257)	(23.734)	(23.309)	(22.757)
Total Operating Costs	(829.491)	(154.192)	(218.492)	(244.094)	(212.713)
EBIT	35.166	(5.456)	10.305	25.470	4.848
EBITDA	71.657	2.701	19.736	34.956	14.264
EBITDA %	8%	2%	9%	13%	7%
Financial result, net	(17.017)	(3.806)	(4.529)	(4.316)	(4.366)
Income tax expense	(7.500)	(24)	(1.326)	(3.921)	(2.230)
Net Profit	10.649	(9.286)	4.449	17.233	(1.748)
Net Profit %	1%	-6%	2%	6%	-1%





- The turnover as well as the EBITDA budgeted will increase consistently, which will be mainly the effects of the M&A operations and the new stretch film business.
- For the Installation segment, domestic infrastructure projects are expected to grow in 2024 as well.
- TeraGlass will continue the strategy of 2023 to switch to non-DIY customers. This switch will be boosted by the newly recruited, experienced sales team, focused on the renovations and new buildings market.
- > The Packaging turnover will grow by 80% due to the commissioning of Opal (stretch film). TeraBio Pack will reach break-even this year.





Financial performance


2023 | 2024B Balance-sheet summary


	TRP Group		
RON '000	2023	2024B	
Intangibles	3.961	6.156	
Tangible assets	421.430	498.793	
Investment Property	5.737	6.608	
Other non-current assets	1.583	1.568	
Non-current assets	432.712	513.124	
Inventories	138.564	183.973	
Trade receivables	154.411	209.038	
Trade payables	(103.329)	(134.455)	
Trade working capital	189.647	258.555	
Other payables	(2.282)	(2.319)	
Other receivables	10.259	2.923	
Other working capital	7.977	604	
Net working capital	197.623	259.159	
Cash and cash equivalents	18.879	1.757	
Bank loans and leases	(252.540)	(341.800)	
Other non current liabilities	(6.908)	(5.444)	
Provisions	(525)	(525)	
Net (debt) / cash	(241.094)	(346.012)	
Subsidies	(76.561)	(102.465)	
Net assets	312.681	323.806	
Share capital & premiums	217.900	217.900	
Reserves	54.259	54.259	
Retained earnings	37.856	48.505	
Non-controlling interest	2.665	3.142	
Equity	312.681	323.806	

Key aspects









- Investment payments were 104 million lei in 2023. For 2024, we plan to invest 53 million lei.
- This year we received 24 million lei in state aid. Next year we will collect 34 million lei.
- Net working capital will increase slightly in 2024 to support regional expansion.



Financial performance

2023 | 2024B CF summary

Cash flow summary, RON `000	2023	2024B
Net profit before tax	5.202	18.149
Net profit adjustments	54.606	49.752
(+) Operating profit before changes in working capital	59.808	67.901
Net impact working capital	4.230	(22.496)
Income tax paid	(4.052)	(7.500)
Interest paid	(13.129)	(13.261)
Income from subsidies	(7.938)	(8.532)
(-) Subtotal changes in working capital and other	(20.888)	(51.789)
=> Cash from operating activities	38.919	16.112
Payments for fixed assets acquisitions	(104.019)	(53.314)
Receipts from sales of fixed assets	872	-
Freiler purchase payments, net of purchased cash	-	(82.309)
Palplast purchase payments, net of purchased cash	-	(3.324)
Receipts from subsidies	23.933	34.437
(+) Net cash used for investments	(79.215)	(104.510)
Net repayments of loans and leasing	48.383	71.276
Dividends received	69	-
Share repurchased	9	-
(-) Net cash from finance activities	48.462	71.276
Net variance	8.166	(17.122)
Cash & Equiv at Jan 1, 2023/ 2024	10.713	18.879
Cash & Equiv at Dec 31, 2023/ 2024	18.879	1.757



